
Nasus Pharma Ltd.: updates and filings
Price
$2.55
November 19, 2026Market cap $23M
What Ploutos Investor adds for Nasus Pharma
Part of Ploutos Investor, €9.99 a month
- The full history in every section
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Current report (foreign company)Form6-K
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 19, 2026Shares registered for employeesFormS-8
- Oct 8, 2026Current report (foreign company)Form6-K
- Sep 18, 2026Current report (foreign company)Form6-K
- Sep 14, 2026Current report (foreign company)Form6-K
- Sep 11, 2026FilingFormEFFECT
- Sep 4, 2026Current report (foreign company)Form6-K
- Sep 1, 2026FilingFormF-3
- Aug 20, 2026FilingFormEFFECT
- Aug 19, 2026Current report (foreign company)Form6-K
- Aug 19, 2026FilingFormPOS AM
- Aug 17, 2026Current report (foreign company)Form6-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 28, 2026Current report (foreign company)Form6-K
- Jun 9, 2026Current report (foreign company)Form6-K
- May 26, 2026Shares registered for employeesFormS-8
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Mar 31, 2026FilingFormEFFECT
- Mar 27, 2026FilingFormPOS AM
- Mar 25, 2026Current report (foreign company)Form6-K
- Mar 25, 2026Annual report (foreign company)for the period to Dec 31, 2025Form20-F
- Mar 16, 2026Current report (foreign company)Form6-K
- Mar 13, 2026FilingFormEFFECT
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | 6-K | Current report (foreign company) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 19, 2026 | S-8 | Shares registered for employees | Document |
| Oct 8, 2026 | 6-K | Current report (foreign company) | Document |
| Sep 18, 2026 | 6-K | Current report (foreign company) | Document |
| Sep 14, 2026 | 6-K | Current report (foreign company) | Document |
| Sep 11, 2026 | EFFECT | Filing | Document |
| Sep 4, 2026 | 6-K | Current report (foreign company) | Document |
| Sep 1, 2026 | F-3 | Filing | Document |
| Aug 20, 2026 | EFFECT | Filing | Document |
| Aug 19, 2026 | 6-K | Current report (foreign company) | Document |
| Aug 19, 2026 | POS AM | Filing | Document |
| Aug 17, 2026 | 6-K | Current report (foreign company) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 28, 2026 | 6-K | Current report (foreign company) | Document |
| Jun 9, 2026 | 6-K | Current report (foreign company) | Document |
| May 26, 2026 | S-8 | Shares registered for employees | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Mar 31, 2026 | EFFECT | Filing | Document |
| Mar 27, 2026 | POS AM | Filing | Document |
| Mar 25, 2026 | 6-K | Current report (foreign company) | Document |
| Mar 25, 2026 | 20-F | Annual report (foreign company)for the period to Dec 31, 2025 | Document |
| Mar 16, 2026 | 6-K | Current report (foreign company) | Document |
| Mar 13, 2026 | EFFECT | Filing | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 30, 2024.
The full analysis
What do Nasus Pharma's filings show?
The filings are where every one of Nasus Pharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.